International Biotechnology Trust is in line for a big jump in its net asset value as its largest holding has been bid for. The trust owned 200,000 shares in Seagen Inc on 10 March, valued at $34.5m, making it the largest position in the trust, accounting for about 10.2% of the portfolio. On 13 March […]
Bellevue Healthcare Trust (BBH) has released its annual results for the 12 month period ending 30 November 2022. BBH reported a NAV total return of -4.1%, and share price total return of -11.9%. This compares to the 14.1% return of its benchmark, the MSCI World Healthcare Index. BBH’s underperformance is largely the result of its […]
JPMorgan China Growth & Income (JCGI) has published its annual results for the year ended 30 September 2022. During the period, JCGI provided an NAV total return of -36.7%, underperforming the MSCI China Index, which declined 22.0%. The Company delivered a return to ordinary shareholders of -38.5%, reflecting a widening in the discount at which […]
International Biotechnology reports a -6.9% return on NAV and -6.4% return to shareholders for the year ended 31 August 2022. However, it beat its performance benchmark, the NASDAQ Biotechnology Index (NBI), which returned -13.8%. This helped the trust claw back some of its underperformance relative to its benchmark over the past five years so that, […]
Biotechnology is an exciting and potentially rewarding sector for investment but for the private investor it is also risky and probably best addressed through collective investment vehicles. After all, development of new drugs is hugely expensive (and thus funding-dependent), scientifically uncertain and fraught with operational challenges and pitfalls. And adding to this is the fact […]
BB Biotech saw an almost 3% rise in its NAV yesterday to CHF51/share, helped by a 36% jump in the share price in one of its holdings – Myovant – triggered by a cash buy-out offer. BB Biotech’s share price, however, was largely unchanged at CHF52.8, which has had the effect of reducing the investment […]
Switzerland’s BB Biotech has opened a new investment position in Rivus Pharmaceuticals, a privately held US biotech developing a mitochondrial-based approach to obesity and cardio-metabolic disease. This was made as part of a $132m Series B financing that is notable for its size and the top-tier syndicate of healthcare specialist investors who have participated. The […]
In early 2021, it looked like the pandemic had been a breakthrough moment for the biotechnology sector. The sector had been critical in the development of Covid-19 vaccines, using new and innovation gene sequencing, while developments in oncology promised a treatment revolution. Share prices were riding high and specialist investment trusts had enjoyed two years […]
Oryx International Growth (OIG) has announced its annual results for the year ended 31 March 2022, during which its NAV fell by 4.57% in what its investment adviser, Harwood Capital, describes as a disappointing year. The adviser says that the portfolio was hampered by a reversal in bond market sentiment towards the biotech and healthcare […]
Over the twelve months to 31 March 2022, Scottish Mortgage returned -13.1% in NAV terms and -9.5% in share price terms as compared to a 12.8% increase in the All-World Index. The chair says “these last couple of years have been extraordinary and do not offer a suitable timeframe over which to judge investment returns” […]
Please review our cookie, privacy & data protection and terms and conditions policies and, if you accept, please select your place of residence and whether you are a private or professional investor.
Due to data protection policies, USA residents can not access our data.
Your content has been curated
